Emerging therapies for dry eye disease

References

• Buckley RJ. Assessment and management of dry eye disease. Eye (Lond). 2018 Feb;32(2):200–203.
   PubMed Web of Science ®Google Scholar
• Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014 Apr;157(4):799–806.
   PubMed Web of Science ®Google Scholar
• Rouen PA, White ML. Dry eye disease: prevalence, assessment, and management. Home Healthc Now. 2018 Mar/Apr;36(2):74–83.
   PubMedGoogle Scholar
• Vehof J, Sillevis Smitt-Kamminga N, Nibourg SA, et al. Predictors of discordance between symptoms and signs in dry eye disease. Ophthalmology. 2017 Mar;124(3):280–286.
   PubMed Web of Science ®Google Scholar
• Findlay Q, Reid K. Dry eye disease: when to treat and when to refer. Aust Prescr. 2018 Oct;41(5): 160–163.
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011 Apr;30(4):379–387.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017 Jul;15(3):334–365.
   PubMed Web of Science ®Google Scholar
• Omega-3. fatty acid supplements do not improve symptoms of dry eye disease. Drug Ther Bull. 2018 Dec;56(12):144.
   PubMedGoogle Scholar
• de Paiva CS, Pflugfelder SC, Ng SM, et al. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019 Sep 13;9(9):Cd010051.
   PubMed Web of Science ®Google Scholar
• Marshall LL, Roach JM. Treatment of dry eye disease. Consult Pharm. 2016 Feb;31(2):96–106.
   PubMedGoogle Scholar
• Clayton JA, Longo DL. Dry Eye. N Engl J Med. 2018 Jun 7;378(23):2212–2223.
   PubMed Web of Science ®Google Scholar
• Downie LE, Keller PR. A pragmatic approach to dry eye diagnosis: evidence into practice. Optom Vis Sci. 2015 Dec;92(12):1189–1197.
   PubMed Web of Science ®Google Scholar
• Dogru M, Nakamura M, Shimazaki J, et al. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013 Dec;22(12):1581–1601.
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017 Jul;15(3):575–628.
   PubMed Web of Science ®Google Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016 Feb 23;2:Cd009729.
   PubMed Web of Science ®Google Scholar
• Higuchi A. Autologous Serum and Serum Components. Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):Des121–des129.
   PubMed Web of Science ®Google Scholar
• Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017 Nov;124(11s):S27–s33.
   PubMedGoogle Scholar
• Shtein RM, Shen JF, Kuo AN, et al. Autologous serum-based eye drops for treatment of ocular surface disease: a report by the American academy of ophthalmology. Ophthalmology. 2020 Jan;127(1):128–133.
   PubMed Web of Science ®Google Scholar
• Drew VJ, Tseng CL, Seghatchian J, et al. Reflections on dry eye syndrome treatment: therapeutic role of blood products. Front Med (Lausanne). 2018;5:33.
   PubMed Web of Science ®Google Scholar
• Heidari M, Noorizadeh F, Wu K, et al. Dry eye disease: emerging approaches to disease analysis and therapy. J Clin Med. 2019 Sep 11;8(9):1439.
   Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014 Jul;40(4):248–256.
   PubMed Web of Science ®Google Scholar
• Fan NW, Dohlman TH, Foulsham W, et al. The role of Th17 immunity in chronic ocular surface disorders. Ocul Surf. 2021 Jan;19:157–168.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Asbell P, Sheppard J. Current and future pharmacological therapies for the management of dry eye. Eye Contact Lens. 2020 Mar;46(Suppl 2):S64–s69.
   PubMedGoogle Scholar
• Kojima T, Dogru M, Kawashima M, et al. Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res. 2020 Jan 29;78:100842.
   Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000 Apr;107(4):631–639.
   PubMed Web of Science ®Google Scholar
• Cequapro.com [Internet]. CEQUA [package insert]. Cranbury (NJ): Sun Pharmaceutical Industries, Inc; 2018 [cited 2021 Feb 17]. Available from: https://cequapro.com/dosing
   Google Scholar
• Cequapro.com [Internet]. Highlights of prescribing information. Cranbury (NJ): Sun Pharma Global FZE; 2019 [cited 2021 Jun 23]. Available from: https://cequapro.com/pdf/CequaPI.pdf
   Google Scholar
• Sheppard JD, Bergmann M, Schechter BA, et al. Phase 3 efficacy (worse-eye analysis) and long-term safety evaluation of OTX-101 in patients with Keratoconjunctivitis Sicca. Clin Ophthalmol. 2021;15:129–140.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Kannarr S, Luchs J, et al. Efficacy and Safety of OTX-101, a novel nanomicellar formulation of Cyclosporine A, for the treatment of Keratoconjunctivitis Sicca: pooled analysis of a phase 2b/3 and phase 3 study. Eye Contact Lens. 2020 Jan;46(Suppl 1):S14–s19.
   PubMedGoogle Scholar
• Lallemand F, Schmitt M, Bourges JL, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017 Aug;117:14–28.
   PubMed Web of Science ®Google Scholar
• Allergan.com [Internet]. Highlights of prescribing information. Irvine (CA): Allergan; 2017 [cited 2021 Jun 23]. Available from: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/RESTASIS_pi.pdf
   Google Scholar
• Deveney T, Asbell PA. Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. Clin Ophthalmol. 2018;12:569–576.
   PubMed Web of Science ®Google Scholar
• Xiidra-ecp.com [Internet]. Mechanism of Action: xiidra® (lifitegrast ophthalmic solution) 5%: novartis pharmaceuticals corporation; 2020 [cited 2020 Dec 15]. Available from: https://www.xiidra-ecp.com/mechanism-of-action
   Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014 Feb;121(2):475–483.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017 Jan;124(1):53–60.
   PubMed Web of Science ®Google Scholar
• Globenewswire.com [Internet]. Oyster point pharma submits new drug application to the U.S. Food and drug administration for OC-01. (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease. Oyster Point Pharma, Inc; 2020 [cited 2021 Feb 17]; [about 7 screens]. Available from: https://www.globenewswire.com/news-release/2020/12/18/2147712/0/en/Oyster-Point-Pharma-Submits-New-Drug-Application-to-the-U-S-Food-and-Drug-Administration-for-OC-01-varenicline-Nasal-Spray-for-the-Treatment-of-Signs-and-Symptoms-of-Dry-Eye-Diseas.html
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Jul 29 Identifier NCT04036292, evaluating the efficacy and safety of OC-01 (Varenicline) nasal spray on dry eye disease; 2019 Feb 23 [cited 2021 Feb 16]; [about 6 screens]. Available from: https://ClinicalTrials.gov/show/NCT04036292
   Google Scholar
• Miles EA, Childs CE, Calder PC. Long-chain polyunsaturated fatty acids (LCPUFAs) and the developing immune system: a narrative review. Nutrients. 2021 Jan 16;13(1):247.
   PubMed Web of Science ®Google Scholar
• Weinberg RL, Brook RD, Rubenfire M, et al. Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar. J Am Coll Cardiol. 2021 Feb 9;77(5):593–608.
   PubMed Web of Science ®Google Scholar
• Ziemanski JF, Wolters LR, Jones-Jordan L, et al. Relation between dietary essential fatty acid intake and dry eye disease and meibomian gland dysfunction in postmenopausal women. Am J Ophthalmol. 2018 May;189:29–40.
   PubMed Web of Science ®Google Scholar
• Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011 Mar;30(3):308–314.
   PubMed Web of Science ®Google Scholar
• Deinema LA, Vingrys AJ, Wong CY, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017 Jan;124(1):43–52.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wu Y, Li G, et al. Efficacy of polyunsaturated fatty acids for dry eye syndrome: a meta-analysis of randomized controlled trials. Nutr Rev. 2014 Oct;72(10):662–671.
   PubMed Web of Science ®Google Scholar
• Asbell PA, Maguire MG, Peskin E, et al. Dry eye assessment and management (DREAM©) study: study design and baseline characteristics. Contemp Clin Trials. 2018 Aug;71:70–79.
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea. 2019 May;38(5):565–573.
   PubMed Web of Science ®Google Scholar
• Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016 Sep;35(9):1185–1191.
   PubMed Web of Science ®Google Scholar
• Sheppard JD Jr., Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe Keratoconjunctivitis Sicca: a randomized double-blind clinical trial. Cornea. 2013 Oct;32(10):1297–1304.
   PubMed Web of Science ®Google Scholar
• Watts P, Sahai A, Kumar PR, et al. A prospective study to assess the role of vitamin D individually and in combination with cyclosporine in the treatment of dry eye in patients with deficient serum 25(OH)D levels. Indian J Ophthalmol. 2020 Jun;68(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Liu J, Dong Y, Wang Y. Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis. Acta Ophthalmol. 2020 Dec;98(8):749–754.
   PubMed Web of Science ®Google Scholar
• Askari G, Rafie N, Miraghajani M, et al. Association between vitamin D and dry eye disease: a systematic review and meta-analysis of observational studies. Cont Lens Anterior Eye. 2020 Oct;43(5):418–425.
   PubMed Web of Science ®Google Scholar
• Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome: summary of a Cochrane systematic review. Br J Ophthalmol. 2019 Mar;103(3):301–306.
   PubMed Web of Science ®Google Scholar
• Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017 Jun 26;6(6):Cd006775.
   PubMedGoogle Scholar
• Hart DE, Simko M, Harris E. How to produce moisture chamber eyeglasses for the dry eye patient. J Am Optom Assoc. 1994Jul;65(7):517–522.
   PubMedGoogle Scholar
• Shen G, Qi Q, Ma X. Effect of moisture chamber spectacles on tear functions in dry eye disease. Optom Vis Sci. 2016 Feb;93(2):158–164.
   PubMed Web of Science ®Google Scholar
• Cohn GS, Corbett D, Tenen A, et al. Randomized, controlled, double-masked, multicenter, pilot study evaluating safety and efficacy of intranasal neurostimulation for dry eye disease. Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):147–153.
   PubMed Web of Science ®Google Scholar
• Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease-past, present, and future. Ocul Surf. 2019 Jan;17(1):20–27.
   PubMed Web of Science ®Google Scholar
• Allergan-web-cdn-prod.azureedge.net [Internet]. TrueTear® intranasal tear neurostimulator professional information guide pleasanton (CA). Allergan; 2018 [cited 2021 Jun 23]. Available from: https://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/labeling/ifu_truetear_professional.pdf
   Google Scholar
• Dieckmann G, Kataguiri P, Pondelis N, et al. In vivo confocal microscopy demonstrates intranasal neurostimulation-induced goblet cell alterations in patients with dry eye disease. Invest Ophthalmol Vis Sci. 2017;58(8): 2694-2694.
   Web of Science ®Google Scholar
• Pondelis N, Dieckmann G, Kataguiri P, et al. Intranasal neurostimulator induces morphological changes in meibomian glands in patients with dry eye disease. Invest Ophthalmol Vis Sci. 2017;58(8): 2235-2235.
   Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Geffin JA, et al. Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: results from two pivotal clinical trials. Ocul Surf. 2019 Jan;17(1):142–150.
   PubMed Web of Science ®Google Scholar
• Olympicophthalmics.com [Internet]. iTEAR ®100; 2020 [cited 2021 Feb 14]; [about 2 screens]. Available from: https://www.olympicophthalmics.com/devices/iTEAR100/
   Google Scholar
• Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):Cd013559.
   PubMedGoogle Scholar
• Sambhi RS, Sambhi GDS, Mather R, et al. Intense pulsed light therapy with meibomian gland expression for dry eye disease. Can J Ophthalmol. 2020 Jun;55(3):189–198.
   PubMed Web of Science ®Google Scholar
• Wladis EJ, Aakalu VK, Foster JA, et al. Intense pulsed light for meibomian gland disease: a report by the American academy of ophthalmology. Ophthalmology. 2020 Sep;127(9):1227–1233.
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM. How to promote and preserve eyelid health. Clin Ophthalmol. 2012;6:1689–1698.
   PubMedGoogle Scholar
• Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2050–2064.
   PubMed Web of Science ®Google Scholar
• Karpecki P. Disinfect the natural way. review of optometry [Internet]; 2019. https://www.reviewofoptometry.com/article/disinfect-the-natural-way
   Google Scholar
• Godin MR, Stinnett SS, Gupta PK. Outcomes of thermal pulsation treatment for dry eye syndrome in patients with Sjogren disease. Cornea. 2018 Sep;37(9):1155–1158.
   PubMed Web of Science ®Google Scholar
• Dompé U.S. Inc. Oxervate full prescribing information; 2019.
   Google Scholar
• Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018 Sep;66:107–131.
   PubMed Web of Science ®Google Scholar
• Sosne G, Kleinman HK. Primary mechanisms of thymosin β4 repair activity in dry eye disorders and other tissue injuries. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110–5117.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Massaro-Giordano G, Nubile M, et al. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. J Cell Physiol. 2017 Apr;232(4):717–724.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020 Jan;127(1):14–26.
   PubMed Web of Science ®Google Scholar
• García-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol. 2019 Mar;97(2):e170–e178.
   PubMed Web of Science ®Google Scholar
• Andia I, Abate M. Platelet-rich plasma: underlying biology and clinical correlates. Regen Med. 2013 Sep;8(5):645–658.
   PubMed Web of Science ®Google Scholar
• Ronci C, Ferraro AS, Lanti A, et al. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfus Apher Sci. 2015 Jun;52(3):300–304.
   PubMed Web of Science ®Google Scholar
• Kengpunpanich S. Novel investigation and management options for meibomian gland dysfunction related to dry eye disease. J Chulabhorn Royal Acad. 2020 Nov 07;2(4):29–38.
   Google Scholar
• O’Neil EC, Henderson M, Massaro-Giordano M, et al. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019 May;30(3):166–178.
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul;15(3):438–510.
   PubMed Web of Science ®Google Scholar
• Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017 Jul;15(3):511–538.
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017 Jul;15(3):284–333.
   PubMed Web of Science ®Google Scholar
• Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol. 2013 Aug;156(2):247–253.e1.
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Baudouin C. From pathogenic considerations to a simplified decision-making schema in dry eye disease. J Fr Ophtalmol. 2013 Jun;36(6):543–547.
   PubMed Web of Science ®Google Scholar
• Vaishya RD, Khurana V, Patel S, et al. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Sep-Oct;6(5):422–437.
   PubMed Web of Science ®Google Scholar
• Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019 Jun;126(6):792–800.
   PubMed Web of Science ®Google Scholar
• Hagan S, Fyfe MCT, Ofori-Frimpong B, et al. Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1443–1453.
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6447–6454.
   PubMed Web of Science ®Google Scholar
• Chao W, Belmonte C, Benitez Del Castillo JM, et al. Report of the inaugural meeting of the TFOS i(2) = initiating innovation series: targeting the unmet need for dry eye treatment. Ocul Surf. 2016 Apr;14(2):264–316.
   PubMed Web of Science ®Google Scholar
• Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877–884.
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017 Jul;15(3):539–574.
   PubMed Web of Science ®Google Scholar
• Novack GD, Asbell P, Barabino S, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017 Jul;15(3):629–649.
   PubMed Web of Science ®Google Scholar
• Adisinsight.springer.com [Internet]. Timbetasin - regenerx biopharmaceuticals Switzerland. © Springer Nature; 2021 [ updated 2021 Oct 21; cited 2021 Feb17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800014482
   Google Scholar
• Adisinsight.springer.com [Internet]. Loteprednol etabonate transmucosal - Kala pharmaceuticals Switzerland. © Springer Nature; 2021 [ updated 2021 May 21; cited 2021 Feb 17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800039532
   Google Scholar
• Adisinsight.springer.com [Internet]. Perfluorohexyloctane ophthalmic solution - Novaliq Switzerland. © Springer Nature; 2021 [ updated 2021 Oct 05; cited 2021 Feb17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800050602
   Google Scholar
• Adisinsight.springer.com [Internet]. Amlisimod - SilkTech biopharmaceuticals Switzerland. © Springer Nature; 2021 [ updated 2021 May 24; cited 2021 Feb 17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800054399
   Google Scholar
• Adisinsight.springer.com [Internet]. Ciclosporin ophthalmic - Novaliq Switzerland: © Springer Nature; 2021 [updated 2021 Sep 23; cited 2021 Feb 17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800037951
   Google Scholar
• Adisinsight.springer.com [Internet]. TOP 1630 Switzerland: © Springer Nature; 2020 [ updated 2020 Apr 28; cited 2021 Feb 17]; [about 3 screens]. Available from: https://adisinsight.springer.com/drugs/800044911
   Google Scholar
• Adisinsight.springer.com [Internet]. Tanfanercept - HanAll Biopharma Switzerland: © Springer Nature; 2020 [ updated 2021 Aug 04; cited 2021 Feb 17]; [about 4 screens]. Available from: https://adisinsight.springer.com/drugs/800045031
   Google Scholar
• Regenerx.com [Internet]. RGN-259: regeneRx; 2020 [cited 2021 Jan 14]; [about 6 screens]. Available from: https://www.regenerx.com/RGN-259
   Google Scholar
• Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491–496.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 May 6 Identifier NCT03937882, Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3; 2019 May 24 [cited 2020 Dec 22]; [about 4 screens]. Available from: https://ClinicalTrials.gov/show/NCT03937882
   Google Scholar
• Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. 2021 May 1;40(5):564–570.
   PubMed Web of Science ®Google Scholar
• Beckman K, Katz J, Majmudar P, et al. Loteprednol etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2020 Sep;36(7):497–511.
   PubMed Web of Science ®Google Scholar
• Sahil A TB. Ocular side-effects of corticosteroids [Internet]. Salt Lake City (UT): Moran Eye Center in partnership with the Eccles Library; [cited 2021 Feb 17]; [about 7 screens]. Available from: http://morancore.utah.edu/basic-ophthalmology-review/ocular-side-effects-of-corticosteroids
   Google Scholar
• Businesswire.com [Internet]. Kala pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA and plans to respond with data from STRIDE 3 trial. Kala pharmaceuticals, inc; 2019 [cited 2021 Jan 3]; [about 3 screens]. Available from: https://www.businesswire.com/news/home/20190808005767/en/Kala-Pharmaceuticals-Receives-FDA-Complete-Response-Letter-for-KPI-121-0.25-NDA-and-Plans-to-Respond-with-Data-From-STRIDE-3-Trial
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Aug 6 - Identifier NCT03616899, safety and efficacy of KPI-121 in subjects with DED; 2018 Jul 10 [cited 2020 Dec 23]; [about 5 screens]. Available from https://ClinicalTrials.gov/show/NCT03616899;2018.
   Google Scholar
• Novaliq.com [Internet]. NOV03: novaliq GmbH; 2021 [cited 2021 Jan 3]; [about 3 screens]. Available from: https://www.novaliq.com/products/nov03
   Google Scholar
• Schmidl D, Bata AM, Szegedi S, et al. Influence of Perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020 Apr;36(3):154–161.
   PubMed Web of Science ®Google Scholar
• Steven P, Scherer D, Krösser S, et al. Semifluorinated alkane eye drops for treatment of dry eye disease–A prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015 Oct;31(8):498–503.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Nov 6 - Identifier NCT03333057, Perfluorohexyloctane (NOV03) for the treatment of signs and symptoms of dry eye disease (DED); 2018 Jan 3 [cited 2021 Jan 4]; [about 5 screens]. Available from: https://ClinicalTrials.gov/show/NCT03333057
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Oct 25 - Identifier NCT00287391, Perfluorohexylcotane (NOV03) for the treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction (Gobi study); 2019 Oct 23 [cited 2021 Jan 4]; [about 5 screens]. Available from: https://ClinicalTrials.gov/show/NCT04139798
   Google Scholar
• Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021 Sep 1;40(9):1132–1140.
   PubMed Web of Science ®Google Scholar
• Infanger DW, Abdel-Naby W, Kalal JJ, et al. Silk-derived protein-4 (SDP-4) inhibits nuclear factor Kappa B (NF-κB) inflammatory signaling that underlies dry eye disease (DED). Invest Ophthalmol Vis Sci. 2019;60(9): 2820-2820.
   Web of Science ®Google Scholar
• Abdel-Naby W, Cole B, Liu A, et al. Treatment with solubilized silk-derived protein (SDP) enhances rabbit corneal epithelial wound healing. PLoS One. 2017;12(11):e0188154.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Mar 26 - Identifier NCT03889886, study to evaluate the safety and efficacy of SDP-4 in subjects with dry eye disease (DED) (SDP-4-CS201); 2019 Apr 16 [cited 2021 Jan 20]; [about 4 screens]. Available from: https://ClinicalTrials.gov/show/NCT03889886
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2020 Sep 2 - Identifier NCT04535947, Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202); 2020 Aug 14 [cited 2021 Jan 20]; [about 5 screens]. Available from: https://ClinicalTrials.gov/show/NCT04535947
   Google Scholar
• Novaliq.com [Internet]. CyclASol®: novaliq GmbH; 2021 [cited 2021 Jan 10]. Available from: https://www.novaliq.com/products/cyclasol/
   Google Scholar
• Taylor M, Ousler G, Torkildsen G, et al. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Clin Ophthalmol. 2019;13:261–275.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Mar 23 - Identifier NCT03088605, safety and efficacy of TOP1630 for dry eye syndrome; 2017 Feb 20 [cited 2021 Feb 10]; [about 4 screens]. Available from: https://ClinicalTrials.gov/show/NCT03088605
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019 Feb 7 -. Identifier NCT03833388, Study of TOP1630 for Dry Eye Syndrome (THEIA-1); 2019 Feb 13 [cited 2021 Feb 10]; [about 5 screens]. Available from: https://ClinicalTrials.gov/show/NCT03833388
   Google Scholar
• Eyewire.news [Internet]. TopiVert announces topline results from phase 2b/3 study of dry eye disease drug candidate: Bryn Mawr Communications, LLC; 2019 [cited 2021 Feb 17]; [about 2 screens]. Available from: https://eyewire.news/articles/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease
   Google Scholar
• Ji YW, Byun YJ, Choi W, et al. Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye. Invest Ophthalmol Vis Sci. 2013 Nov 15;54(12):7557–7566.
   PubMed Web of Science ®Google Scholar
• Lee HB, Choi HJ, Cho SM, et al. Efficacy of HL036 versus Cyclosporine A in the treatment of naturally occurring canine Keratoconjunctivitis Sicca. Curr Eye Res. 2018 Jul;43(7):889–895.
   PubMed Web of Science ®Google Scholar
• Shin M, Ahn H, Bernton E, et al. HL036 ophthalmic solution, a topical TNF-α inhibitor, significantly improves signs and symptoms of dry eye in a phase 2 clinical trial (VELOS-1). Invest Ophthalmol Vis Sci. 2019;60(9): 249-249.
   Web of Science ®Google Scholar
• Mandell KJ, Clark D, Chu DS, et al. Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement. J Ocul Pharmacol Ther. 2020 Dec;36(10):732–739.
   PubMed Web of Science ®Google Scholar
• Clark D, Cavanagh B, Shields AL, et al. Clinically relevant activity of the novel RASP inhibitor reproxalap in allergic conjunctivitis: the phase 3 alleviate trial. Am J Ophthalmol. 2021 May 1;230:60–67.
   PubMed Web of Science ®Google Scholar
• Clark D, Sheppard JD, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021 May;37(4):193–199.
   PubMed Web of Science ®Google Scholar